Title |
Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients
|
---|---|
Published in |
Cochrane database of systematic reviews, October 2005
|
DOI | 10.1002/14651858.cd003961.pub2 |
Pubmed ID | |
Authors |
A Webster, R C Woodroffe, R S Taylor, J R Chapman, J C Craig |
Abstract |
Kidney transplantation is the treatment of choice for most patients with end-stage renal disease (ESRD). Standard protocols in use typically involve three drug groups each directed to a site in the T-cell activation or proliferation cascade which are central to the rejection process: calcineurin inhibitors (e.g. cyclosporin, tacrolimus), anti-proliferative agents (e.g. azathioprine, mycophenolate mofetil) and steroids (prednisolone). It remains unclear whether new regimens are more specific or simply more potent immunosuppressants. |
Mendeley readers
The data shown below were compiled from readership statistics for 182 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
United States | 1 | <1% |
Unknown | 180 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 25 | 14% |
Researcher | 20 | 11% |
Student > Bachelor | 20 | 11% |
Student > Ph. D. Student | 19 | 10% |
Student > Postgraduate | 13 | 7% |
Other | 28 | 15% |
Unknown | 57 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 68 | 37% |
Nursing and Health Professions | 12 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 11 | 6% |
Agricultural and Biological Sciences | 5 | 3% |
Computer Science | 3 | 2% |
Other | 17 | 9% |
Unknown | 66 | 36% |